Actym Therapeutics, Inc. Email Format

Biotechnology ResearchCalifornia, United States2-10 Employees

Actym Therapeutics, Inc. is a Berkeley, California-based biotechnology company focused on cancer immunotherapy. Its lead candidate ACTM-838 leverages the STACT platform to deliver a continuously active STING and an IL-15plex payload directly to myeloid cells within the tumor, promoting local activation of innate and adaptive immunity. The STACT platform deploys a systemically administered, genetically modified bacterial vehicle to ferry multiple payloads to the disease site, where they amplify locally to generate a therapeutic effect.

The approach aims to convert immunologically cold tumors into hot ones while limiting systemic immune activation, and it is described as complementary to immunotherapies hampered by the tumor’s suppressive environment. In 2024, Actym appointed Mary J. Janatpour as Chief Scientific Officer, reflecting leadership expansion as the company advances its clinical program, with Phase 1a/b updates expected in the third quarter of 2025.

Get verified Actym Therapeutics, Inc. emails free

Company overview Employee directory